Galmed shareholders approve proposal at special meeting

Galmed Pharmaceuticals Ltd. reported that it held a Special General Meeting of Shareholders on March 5, 2026.

Rhea-AI Filing Summary

Galmed Pharmaceuticals Ltd. reported that it held a Special General Meeting of Shareholders on March 5, 2026. At this meeting, shareholders voted on a proposal described in the proxy statement that was previously furnished to the SEC on February 9, 2026. The proposal was approved by the required majority under the Israeli Companies Law, meaning it received enough votes for adoption under Galmed’s home-country rules. The company also noted that this report is incorporated by reference into its existing registration statements on Form S-8 and Form F-3, linking the meeting outcome into its broader U.S. securities registration framework.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Galmed Pharmaceuticals Ltd. (GLMD) report in its March 2026 Form 6-K?

Galmed reported that it held a Special General Meeting of Shareholders on March 5, 2026, where shareholders voted on a proposal described in a February 9, 2026 proxy statement. The company confirmed that this proposal was approved with the requisite majority.

Was the proposal at Galmed Pharmaceuticals’ March 5, 2026 special meeting approved?

Yes, the proposal presented at Galmed Pharmaceuticals’ Special General Meeting of Shareholders on March 5, 2026 was approved. The company states it received the requisite majority in accordance with the Israeli Companies Law, meaning it met the legal voting threshold for adoption.

When did Galmed Pharmaceuticals (GLMD) hold its Special General Meeting of Shareholders?

Galmed Pharmaceuticals held its Special General Meeting of Shareholders on March 5, 2026. At this meeting, shareholders voted on a proposal previously detailed in a proxy statement furnished to the SEC on February 9, 2026, and that proposal was subsequently approved.

Where was the proposal for Galmed’s March 5, 2026 meeting originally described?

The proposal voted on at Galmed’s March 5, 2026 Special General Meeting was described in a proxy statement included as an exhibit to a Form 6-K. That Form 6-K was furnished to the U.S. Securities and Exchange Commission on February 9, 2026 by the company.

How does this Galmed Form 6-K relate to the company’s registration statements?

Galmed states that this Form 6-K is incorporated by reference into several existing registration statements. These include its Form S-8 registration statements and its Form F-3 registration statements, effectively linking the meeting result into those U.S. securities filings.

Under which legal framework was Galmed’s shareholder vote assessed?

The shareholder vote at Galmed’s Special General Meeting was assessed under the Israeli Companies Law, 5759-1999. The company notes that the proposal received the requisite majority under this law, indicating compliance with its home-country corporate governance standards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 04:05 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of March 2026

001-36345

(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

c/o Meitar Law Offices Abba Hillel Silver Rd.,

Ramat Gan, 5250608

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover

Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On March 5, 2026, Galmed Pharmaceuticals Ltd. (the “Company”) held a Special General Meeting of Shareholders (the “Meeting”). At the Meeting, the Company’s shareholders voted on the proposal described in the proxy statement for the Meeting included as an exhibit to the Company’s report on Form 6-K furnished by the Company with the Securities and Exchange Commission on February 9, 2026. The proposal brought before the shareholders at the Meeting was approved by the shareholders of the Company with the requisite majority in accordance with the Israeli Companies Law, 5759-1999.

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration Nos. 333-206292, 333-227441, 333-284163 and 333-290399) and the Company’s Registration Statement on Form F-3 (Registration Nos. 333-272722 and 333-283241).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Galmed Pharmaceuticals Ltd.
Date: March 5, 2026	By:	/s/ Allen Baharaff
		Allen Baharaff
		President and Chief Executive Officer